Moreover, it is currently clear that targeting activation of the NLRP3 inflammasome and the related endpoints (IL-1β, IL-18, pyroptosis) will provide new insights into the development of novel therapeutic options in IBD and other diseases mediated by NLRP3; however, there are still no evidence-based studies in relation to the pediatric age group. This evidence concerns the gene IL18 and irritable bowel syndrome.